STXBP1 program (Abilita Therapeutics)

The STXBP1 program is an early-stage therapeutic candidate being developed by Abilita Therapeutics for the treatment of rare neurological and potentially immunological disorders. The program utilizes Abilita's proprietary **Humanized Helical Evolution (HHE™)** platform, which is designed to stabilize complex membrane proteins like **Syntaxin-binding protein 1 (STXBP1)** in their native, functional conformations. STXBP1 is a critical component of the SNARE complex, essential for the docking and fusion of synaptic vesicles and the subsequent release of neurotransmitters in the brain. Mutations in the STXBP1 gene are the primary cause of STXBP1-related encephalopathy (including Ohtahara syndrome), characterized by severe epilepsy and developmental delays. By creating stabilized "Enabled Membrane Proteins" (EMPs), Abilita facilitates the discovery of high-affinity therapeutic agents, such as monoclonal antibodies or small molecules, that can modulate the target's function. Although some pipeline contexts associate this program with **Good Syndrome** (a rare immunodeficiency associated with thymoma), this likely reflects an exploratory application or a data alignment artifact in source registries, as the target is classically linked to neurodevelopmental disorders. The program is currently in the discovery and lead optimization phases and is available for partnering.

Other names

STXBP1-HHE programSTXBP-1-HHE programSTXBP 1-HHE programAbilita Therapeutics-STXBP1-HHE-Good Syndrome